Medical cannabis patients in 18 states can be convicted of impaired driving based solely on detectable THC in their blood, even when showing no signs of actual impairment—a standard that does not apply to users of prescription benzodiazepines like Xanax.
The disparity highlights a persistent gap in how states treat legal cannabis use versus other prescription medications. While prosecutors must prove actual impairment for drivers on prescribed benzodiazepines—drugs with well-documented crash risks—THC's mere presence or concentration above an arbitrary threshold can be enough for a conviction in states with per se or zero-tolerance cannabis DUI laws.
The Science Problem
Blood THC levels correlate poorly with impairment, particularly among regular medical users who maintain higher baseline concentrations. Research indicates that chronic consumers can have detectable THC in their system days or weeks after use, long after any psychoactive effects have worn off. A 2020 study in JAMA Psychiatry found no reliable correlation between THC blood concentration and driving performance in regular users.
Yet 18 states maintain laws that presume impairment based on THC presence or specific blood concentration levels, typically 5 nanograms per milliliter. These per se limits were often adopted before states legalized medical cannabis, creating a legal contradiction: patients can legally use cannabis as prescribed but face automatic DUI charges if stopped while driving.
Different Standards for Different Drugs
Benzodiazepines present a clearer impairment profile. Clinical evidence shows these medications significantly increase crash risk and produce measurable psychomotor effects. But prosecutors pursuing DUI charges against drivers on prescribed Xanax, Valium, or similar drugs must demonstrate actual impairment through field sobriety tests, officer observations, or drug recognition expert evaluations.
The same standard does not apply in states with cannabis per se laws. A medical marijuana patient in Pennsylvania or Montana can be convicted based on a blood test alone, regardless of driving behavior or sobriety test results.
Medical Patients in Legal Limbo
The American Civil Liberties Union and several patient advocacy groups have challenged these laws as discriminatory. In 2016, the Pennsylvania Supreme Court ruled that medical marijuana patients could not be prosecuted under the state's zero-tolerance provision, but many states have not followed suit.
Colorado, which legalized recreational cannabis in 2012, maintains a 5 nanogram per se limit while simultaneously issuing medical marijuana cards. The state's own Department of Transportation has acknowledged that regular users may exceed this threshold without being impaired.
What Comes Next
Several states are reconsidering their approach. A 2023 bill in Montana would have required proof of actual impairment for cannabis DUI charges but stalled in committee. Nevada recently adjusted its law to allow medical marijuana patients to present evidence that their THC level does not indicate impairment.
The National Highway Traffic Safety Administration has not established a reliable THC impairment threshold, stating in multiple reports that such a standard may not be scientifically feasible given individual variation in tolerance and metabolism. Until states adopt impairment-based prosecution standards similar to those used for prescription medications, medical cannabis patients remain vulnerable to conviction based on biochemistry rather than behavior.
This article is based on original reporting by hightimes.com.